Arcus falls after co and Gilead scrap late-stage trial of cancer drug combo
ReutersDec 12, 2025 1:47 PM
Shares of drug developer Arcus Biosciences RCUS.N fall 8.5% to $23 premarket
Co says it and Gilead GILD.O will stop a late-stage study testing their experimental cancer drug combination in patients with advanced stomach and esophageal cancers after it failed to show a survival benefit
An interim analysis showed the combination of GILD's domvanalimab and RCUS' zimberelimab with chemotherapy did not improve overall survival compared to Bristol Myers Squibb's BMY.N nivolumab and chemotherapy
Up to last close, stock had risen 68.8% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
Global Flight to Safety Intensifies as Gold, Silver, and Platinum Hit New Highs — ‘Currency Wars’ Author Predicts $10,000 Gold and $200 Silver
TradingKey - Since the start of 2025, silver, which offers both investment attributes and industrial utility, has surged by approximately 150%.TradingKey
Fri, Dec 26
TradingKey 2025 Markets Recap & Outlook | Gold Records Its Best Performance in Half a Century, Wall Street Predicts $5,000 Breach in 2026
TradingKey - Amid escalating global economic uncertainty, gold is experiencing its best performance since 1979, achieving its largest increase in 46 years. As 2025 draws to a close, major Wall Street institutions have confirmed gold's status as the best safe-haven asset, with a consensus forming thaTradingKey
Fri, Dec 26
TradingKey 2025 Markets Recap & Outlook | Bitcoin Price Repeatedly Hits New Highs, 2026 Can BTC Write Another Legend?
Multiple tailwinds in 2025 propelled Bitcoin to new highs, but many of these positives have already been priced in. In 2026, Bitcoin faces challenges such as liquidity tightening, as well as regulatory and monetary policy uncertainties. Wall Street is divided on Bitcoin's future outlook, with targetTradingKey
Fri, Dec 26
TradingKey 2025 Markets Recap & Outlook | Global Central Banks 2026 amid Post‑Easing Recovery and Diverging Paths
TradingKey - In 2025, major global central banks will largely maintain an accommodative stance, but the policy pace will decelerate notably. As the easing cycle draws to a close, how will global monetary policy evolve?TradingKey
Thu, Dec 25
Ripple Price Prediction: Why Is XRP Price Falling? Can It Rise to $10 in the Future?
XRP has weakened this year due to profit-taking, capital outflows, and its correlation with Bitcoin. Despite support from potential spot ETFs and positive regulatory developments, significant market divergence, liquidity uncertainty, and macroeconomic uncertainty remain high. XRP's price is likely tTradingKey
Wed, Dec 24
Tradingkey
